How may we assist you?

Archive: "News releases"

  • Pepscan COVID-19 Update – Facility Operational

    We would like to inform you that the Pepscan facility is operational. This allows us to proceed serving and supporting scientists in their work on amongst others diagnostic and vaccine related COVID-19 projects and treatment of cancer patients with personalized peptide vaccines. By implementing a shift-schedule and additional precautionary measures to minimize physical interaction amongst our staff, we are able to continue the production and delivery of R&D and clinical peptides so far. Our sales team works offsite, but strives …

  • Pepscan Webinar: Next generation peptide discovery

    Learn about Pepscan’s phage display technology used to discover highly constrained peptides with enhanced affinity, selectivity and proteolytic stability. April 2nd – 16.00 CEST – 10.00 ET – 7.00 PT Register here We invite you to join our upcoming webinar featuring Pepscan experts Prof. Peter Timmerman and Dr. Michael Goldflam sharing their expertise on de novo discovery of the best peptide binders for your target protein of interest.  This webinar will discuss Pepscan’s proprietary phage display CLIPSTM technology platform, which …

  • Pepscan Case – Use of 3D-structured peptides mimicking monoclonal antibody binding site to develop VEGF targeting vaccine

    Therapeutic targeting of the VEGF signaling axis by the VEGF neutralizing monoclonal antibody bevacizumab has clearly demonstrated clinical benefit in cancer patients. To improve this strategy using a polyclonal approach, a vaccine targeting VEGF was developed for medical oncology using 3D-structured peptides that mimic the bevacizumab binding site. “Before the start of this RVO-funded project a small research group, including myself, had developed a general approach to protein-mimics using scaffold-technology. We wanted to apply this approach to the mimicry of …

  • Antibody epitope mapping – A crucial and inevitable step in therapeutic antibody development

    Why Pepscan is the provider of epitope mapping services in 58% of last year’s European patent publications Mapping the epitopes of an antibody is an inevitable step in therapeutic antibody development. Epitope mapping not only serves intellectual property purposes, but also provides the data needed for antibody selection and characterization and gives the information needed for FDA and EMA regulatory filings. Dennis Flierman and Martin Ham visited the 2019 Antibody Engineering & Therapeutics Conference in San Diego and spotted the …

  • Surpassing expectations via joint innovation

    Developing the next generation hydrogel using Pepscan’s RGD bicyclic peptides Pepscan and 13 other partners participated in the Horizon 2020 – Marie Skodowska-Curie project BIOGEL’s consortium. “Our primary task was to fabricate cell-specific bicyclic peptides that can be utilized to modify the hydrogels with specific integrin-binding domains, in this case RGD, to direct cells,” says Peter Timmerman, CSO at Pepscan. Paul Kouwer, Assistant Professor at Radboud University, adds: “Our preliminary results show a thousand-fold increase in cell binding. You can …

  • Pepscan at Immuno-Oncology Summit/TMB & Neoantigen Stream

    “A great opportunity to share our knowledge and experience!” The battle to outsmart cancer isn’t won yet. Scientists are continuously looking for new and better approaches to tackle this disease. Cancer treatment with a personalized neoantigen peptide vaccine is a rising star among these approaches. Recently Pepscan has positioned itself as a critical partner in several collaborative clinical trials with these personalized anti-cancer vaccines. “The neoantigen supply chain is focused on efficiency and speed. To meet this need, we have …

  • Passion for peptides – The people behind Pepscan

    “I’m a generalist working at the interface of chemistry, biology and physics” Velten Horn started working for Pepscan at the beginning of this year. “Shortly after joining Pepscan I was awarded my PhD at Leiden University. There I studied protein-protein and peptide-protein interactions on a structural level with a wide range of biophysical and computational techniques.” Velten recently transferred to Pepscan’s Department of Epitope Mapping working as a Scientist. “It is a perfect fit,” he recalls. Velten is originally from …

  • Pepscan doubles GMP production capacity to facilitate clients’ growth

    Today, Pepscan announced that its GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides. The doubled GMP production capacity enables Pepscan to guarantee short production timelines. It also gives clients the benefit of collaborating with a single expert partner on the way from R&D to the clinic, resulting in maximum efficiency while also saving time. …

  • CLIPS scaffolds used in phage display to boost drug discovery

    Phage display is a technology that allows de novo discovery of peptidic binders against any protein target of interest by exploring DNA-encoded peptide libraries, exceeding billions of different members. Our team of experts developed a unique phage display platform for the discovery of high-quality lead candidates with affinity for clients’ targets. Unique CLIPS scaffold portfolio By incorporating Pepscan’s unique CLIPS scaffold portfolio, we optimized our phage display platform for the identification of CLIPS constrained peptides, a class of highly-constrained peptides …

  • Passion for Peptides – The people behind Pepscan

    “Solving the puzzle brings me the greatest pleasure” Jeroen Bouwhuis has been working at Pepscan for almost six years. “I started here as an intern, and over the years I’ve really grown into the company.” Besides being one of the individuals responsible for manufacturing high-quality peptides, Jeroen is part of Pepscan’s Manufacturing, Science and Technology (MS&T) team led by Chief Scientific Officer Peter Timmerman. “What I really like about Pepscan is that we try to serve our clients under almost …

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the Pepscan website. However, if you would like to, you can change your cookie settings at any time in your browser.
Cookie Policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies